Physician profile
Tripta Singh
NPI 1760874770
$2,470.39
in general payments reported to CMS, 2019-2025
36 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $86.90 · 2021: $560 · 2022: $486 · 2023: $108 · 2024: $243 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $607.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $312.69 | 2019-2025 | Vraylar |
| Amgen INC. | $227.89 | 2019-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.69 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $128.74 | 2019-2024 | Jardiance |
| Pfizer INC. | $128.17 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $100.53 | 2019-2023 | Breztri |
| Exact Sciences Corporation | $49.20 | 2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $42.86 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.48 | 2022 | |
| Amarin Pharma, INC. | $39.80 | 2019-2020 | |
| Abbott Laboratories | $39.65 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $36.91 | 2022-2025 | Lagevrio |
| Astellas Pharma US INC | $33.62 | 2025 | Veozah |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insightec,INC | $28.85 | 2025 | Exablate |
| Aerin Medical INC. | $28.65 | 2025 | |
| Glaxosmithkline, LLC. | $27.79 | 2021-2025 | Shingrix, Arexvy |
| Nestle Healthcare Nutrition INC. | $25.86 | 2021 | |
| Eyevance Pharmaceuticals LLC | $25.36 | 2021 | |
| Hikma Pharmaceuticals USA | $25.36 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $24.56 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.22 | 2021 | |
| Ethicon US, LLC | $22.37 | 2021 | |
| Recor Medical INC | $21.31 | 2025 | Paradise Ultrasound Renal Denervation System |
| Esperion Therapeutics, INC. | $20.14 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.83 | 2022 | |
| Seqirus USA INC | $18.08 | 2024 | Flucelvax, Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.75 | 2021 | |
| Endo Pharmaceuticals INC. | $14.76 | 2021 | |
| Eisai INC. | $14.05 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.80 | 2022 | |
| Boston Scientific Corporation | $13.21 | 2019 | |
| Bausch Health US, LLC | $12.47 | 2021 | |
| Qiagen, LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tripta Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.